PMA P110019S108

Device
XIENCE PRIME, XIENCE PRIME SV/LL, XIENCE Xpedition, XIENCE Xpedition SV/LL, XIENCE Alpine, and XIENCE Sierra EVEROLIMUS
Applicant
Abbott Vascular
Product code
NIQ
Decision date
2020-03-19
Generic name
Coronary drug-eluting stent
Approval order statement
Approval for changing the ethylene oxide (EO) sterilization release process for the affected products from the traditional method of biological indicator testing to a parametric release process.

Current openFDA PMA Record#

Device
XIENCE PRIME, XIENCE PRIME SV/LL, XIENCE Xpedition, XIENCE Xpedition SV/LL, XIENCE Alpine, and XIENCE Sierra EVEROLIMUS
Applicant
Abbott Vascular
PMA number
P110019
Supplement
S108
Product code
NIQ
Generic name
Coronary drug-eluting stent
Decision date
2020-03-19
Decision code
APPR
Date received
2019-09-26
Supplement type
135 Review Track For 30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Approval order statement
Approval for changing the ethylene oxide (EO) sterilization release process for the affected products from the traditional method of biological indicator testing to a parametric release process.